Outlook Therapeutics (OTLK) EPS (Weighted Average and Diluted): 2016-2020
Historic EPS (Weighted Average and Diluted) for Outlook Therapeutics (OTLK) over the last 3 years, with Sep 2020 value amounting to $0.02.
- Outlook Therapeutics' EPS (Weighted Average and Diluted) was N/A to $0.02 in Q3 2020 from the same period last year, while for Sep 2020 it was -$0.25, marking a year-over-year change of. This contributed to the annual value of -$4.06 for FY2024, which is 13.98% up from last year.
- Per Outlook Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at $0.02 for Q3 2020, which was up 166.67% from -$0.03 recorded in Q2 2020.
- Outlook Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.02 for Q3 2018, and its period low was -$1.60 during Q2 2016.
- In the last 2 years, Outlook Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.03 in 2020 and averaged -$0.19.
- Examining YoY changes over the last 5 years, Outlook Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 107.41% in 2018 and a maximum decrease of 18.18% in 2018.
- Outlook Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.24 in 2016, then declined by 12.50% to -$0.27 in 2017, then soared by 107.41% to $0.02 in 2018, then reached $0.02 in 2020.
- Its last three reported values are $0.02 in Q3 2020, -$0.03 for Q2 2020, and $0.02 during Q3 2018.